The reverse split is a routine Nasdaq compliance action for a micro-cap pre-revenue company. Monitor for potential Nasdaq delisting risk if the post-split share price fails to maintain the $1.00 minimum bid requirement. No change in business outlook or cash runway.
Price Chart
Executive Summary
Autonomix Medical filed an 8-K to announce a 1-for-21 reverse stock split, effective June 24, 2026, reducing outstanding shares from ~11.4M to ~543,000. The split is a Nasdaq compliance measure for a micro-cap pre-revenue medical device company with a $4M market cap, and does not change the company's fundamentals or cash position.
Key Facts
- Reverse stock split at 1:21 ratio, effective 12:01 a.m. ET on June 24, 2026.
- Outstanding shares reduced from 11,409,344 to approximately 542,000 (543,000 per press release).
- Authorized shares remain unchanged at 500 million.
- Net loss for FY2026 was $16.7M, up from $11.4M in FY2025.
- Post-split net loss per share for FY2026 is $(48.80), compared to $(137.44) for FY2025.
- Weighted average shares outstanding (basic/diluted) retroactively adjusted to 342,539 for FY2026 and 83,020 for FY2025.
- Company is pre-revenue with no cleared products; technology is investigational.
- Market cap is approximately $4M.
Financial Impact
No direct financial impact; reverse split is a mechanical share consolidation. Net loss for FY2026 was $16.7M, up 46.5% from $11.4M in FY2025.
Risk Factors
- Post-split stock may still fail to maintain Nasdaq minimum bid price of $1.00.
- Pre-revenue status with no cleared products and growing net losses ($16.7M in FY2026).
- Extremely low market cap ($4M) and thin liquidity post-split.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-021495 |
| Exhibit: ex_979198.htm | 0001437749-26-021495 |
| Document: 0001437749-26-021495-index-headers.html | 0001437749-26-021495 |
| Document: 0001437749-26-021495-index.html | 0001437749-26-021495 |
| Document: 0001437749-26-021495.txt | 0001437749-26-021495 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 13d ago | 3 | $3.01 | awaiting T+20 | — | $2.10 (−30.23%) |
Oct 2, 2026 25d ago | Press Release | $3.78 | awaiting T+20 | — | $2.10 (−44.44%) |
Sep 16, 2026 5w ago | 8-K | $4.12 $3.01 | ▼ −26.94% | ▼ −30.12% | $2.10 (−49.03%) |
Sep 16, 2026 5w ago | EFFECT | $4.12 $3.01 | ▲ +26.94% | ▲ +30.12% | $2.10 (+49.03%) |
Sep 11, 2026 6w ago | 424B5 | $4.33 $3.10 | ▲ +28.41% | ▲ +30.67% | $2.10 (+51.50%) |
Sep 4, 2026 7w ago | S-3 | $4.58 $3.47 | ▲ +24.24% | ▲ +25.95% | $2.10 (+54.15%) |
Aug 26, 2026 8w ago | 8-K | $5.63 $4.07 | ▼ −27.71% | ▼ −27.20% | $2.10 (−62.70%) |
Aug 5, 2026 11w ago | EFFECT | $12.10 $4.50 | ▼ −62.81% | ▼ −62.21% | $2.10 (−82.64%) |
Jul 28, 2026 12w ago | 8-K | $2.75 $7.19 | ▲ +161.45% | ▲ +158.07% | $2.10 (−23.64%) |
Jul 15, 2026 14w ago | 8-K | $4.92 $6.86 | ▼ −39.43% | ▼ −35.81% | $2.10 (+57.32%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers